London: AstraZeneca Plc and Daiichi Sankyo Co.’s Enhertu delayed the advance of a common type of breast cancer by more than a ...

Treating breast cancer patients with AstraZeneca’s experimental pill camizestrant at the first sign of resistance to standard treatments cut the risk of disease progression or death by half, a finding ...

In comments posted in response to the Trump administration’s pharma tariff investigation, companies and industry groups ...

Study results unveiled at ASCO show combining Enhertu with Perjeta can significantly delay tumor growth versus a regimen that ...

DelveInsight's,“ Advanced Melanoma Pipeline Insight 2025 ” report provides comprehensive insights about 55+ companies and 60+ pipel ...

So far, China has made no official public threat about weaponizing its dominant position in this segment of the pharmaceutical industry. But Trump’s tariffs on the sector, if imposed, could worsen ...

Ascentage Pharma (NASDAQ: AAPG; HKEX: 6855), a global biopharmaceutical company dedicated to addressing unmet medical needs in cancers, announced that it has released the latest data from a Phase ...

Governor Revives ‘Asset Test’ For Medi-Cal Applicants: Gov. Gavin Newsom has proposed tackling the rising costs of Medi-Cal ...

Arguably the most notable of the FDA’s upcoming decisions is that regarding Gilead’s twice-yearly HIV prophylaxis lenacapavir ...

The drug candidate, trevogrumab, in combination with Novo Nordisk's popular obesity drug Wegovy, chemically known as semaglutide, helped patients preserve muscle and increase fat loss in patients, ...

It might sound basic, but data shows that focusing on healthy food and structured exercise might help patients with cancer live longer or respond to therapy. Other cancer news reports on immunotherapy ...

AstraZeneca's camizestrant and Pfizer's vepdegestrant extended progression-free survival in trials in advanced ESR1-mutated breast cancer.